Résumé
Cypermethrin was administered to Heteropneustes fossilis in chronic concentration to determine lesion of liver as indicators of tissue damage. The cypermethrin dose used was 1/4 of 96 hr LC50. Histopathological changes in liver ranged from vacuolization, necrosis, fibrosis of perivascular region and disposition of yellow brown grains at different time of exposure viz; 20th, 30th, 40th and 60th days.
Sujets)
Animaux , Poissons-chats , Fibrose , Hépatocytes/effets des médicaments et des substances chimiques , Insecticides/toxicité , Foie/effets des médicaments et des substances chimiques , Pyréthrines/toxicité , Polluants chimiques de l'eau/toxicitéRésumé
Fibrosis of organs and tissues are major causes of morbidity and mortality in human. The currently available pharmacologically based treatments are unsatisfactory. As an experimental animal model antitumor antibiotic drug bleomycin (BLM) is widely used to produce lung fibrosis. The present study has been undertaken to investigate the possible role of a potent immunomodulator Staphylococcus protein-A (SpA) in the modulation of lung lesions caused by treatment of BLM. In mice BLM, 0.5 mg in 200 microliters of normal saline and SpA, 6 micrograms in 200 microliters of normal saline was administered singly or in combination twice a week for 4 weeks. The fibrotic lesions in the lungs were observed after 4 weeks of BLM treatment. After 4 weeks treatment of SpA, the hyperreactive changes in bronchi and bronchioles were observed. In the co-treatment group of BLM and SpA, the effects observed were in the form of enhanced lesions in the lung parenchyma. Moreover, the pleural lesions were also observed in co-treatment group (BLM + SpA). Opposite to the assumption, SpA being a potent immunomodulator was not able to reduce the lung lesions produced by BLM.
Sujets)
Animaux , Antibiotiques antinéoplasiques/toxicité , Bléomycine/toxicité , Synergie des médicaments , Mâle , Souris , Fibrose pulmonaire/induit chimiquement , Protéine A staphylococcique/toxicitéRésumé
Staphylococcus protein-A (SpA) was administered (ip) to Balb/c male mice for two weeks, twice a week at the dose level of 1, 6 and 12 micrograms in 200 microliters of normal saline. A significant change in the relative weights of liver, spleen, thymus, tracheobronchial lymph node, lung and testis was observed in 1 microgram SpA treatment group. In the adrenal, marked changes at the dose level of 1 microgram SpA treatment after 2 weeks were observed in the form of cellular proliferation on zona glomerulosa (ZG) and zona fasciculata (ZF) of adrenal cortex. With 6 and 12 micrograms SpA, adrenocortical masses were observed outside the capsule of adrenal gland. The enhanced effects of SpA at 4 weeks after treatment with the dose level of 6 and 12 micrograms were in the form of adrenal cell masses outside adrenal gland and histological changes in the adrenal cortex. The results suggest that long term and high doses therapy with SpA may be a risk factor to sensitive endocrine glands.